Mark Blaxill

Mark Blaxill is co-founder and Executive Director of XLP Capital, a firm founded in 2015 and focused on technology strategy development, new technology business incubation and technology-based investments. Before starting XLP, Mr. Blaxill was a co-Founder and Managing Partner of 3LP Advisors, a firm focused on IP strategy development, patent transactions and IP-based investments. Previous to the launch of 3LP in 2008, he was a 25-year veteran of The Boston Consulting Group, where as senior vice president and partner, he headed the firm's Strategy Practice and recruited BCG’s core IP Strategy team. In this role, he launched the firm's Intellectual Property practice, developed proprietary tools for technology analysis, and co-authored BCG's first patent application.

He is the co-author of The Invisible Edge: Taking Your Strategy to the Next Level Using Intellectual Property (Portfolio, 2009), which was named Best Strategy Book in 2009 by a leading business journal. He has been named one of “The World’s Leading IP Strategists” by IAM Magazine. Mark credits that honor to XLP’s unique integration of the quantitative analyses of technology, patents, business and financial performance.

Mark is also the father of a daughter diagnosed with autism, Chairman and co-founder of the Canary Party and Health Choice, Editor-at-Large for Age of Autism, a former director of SafeMinds and a frequent speaker at autism conferences. He writes often on autism, science and public policy issues for Age of Autism and has published a number of articles, letters and commentaries on autism in journals such as Public Health Reports, the International Journal of Toxicology, the Journal of Autism and Developmental Disorders, Frontiers in Pediatrics, Neurotoxicology and Medical Hypotheses. He has also been invited to peer review articles in journals such as the New England Journal of Medicine, the American Journal of Epidemiology, Pediatrics and the International Journal of Toxicology. As part of his advocacy work, he has testified before the Immunization Safety Review of the Institute of Medicine (2001), served on a Blue Ribbon Panel on Vaccine Safety (2004), initiated a symposium sponsored by the National Institute of Environmental Health Sciences entitled  “Environmental Factors in Neurodevelopmental Disorders” (2005) and a workshop sponsored by the Institute of Medicine entitled “Autism and the Environment: Challenges and Opportunities for Research” (2007). He was a panelist at a “Meeting on Evaluating Reasons for ASD Trends” co-sponsored by the Centers for Disease Control and Autism Speaks (2011) and at a hearing “1 in 88 Children: A Look Into the Federal Response to Rising Rates of Autism” called by the House of Representatives’ Oversight and Government Reform Committee (2012). He has co-authored two books with Dan Olmsted: The Age of Autism: Mercury, Medicine and a Man-made Epidemic, (Thomas Dunne, September 2010) and Vaccines 2.0: The Careful Parent's Guide to Making Safe Vaccination Choices for Your Family (Skyhorse Publishing, February 2015). His third book with Dan, Denial: How Refusing to Face the Facts About Our Autism Epidemic Hurts Children, Families—and our Future (Skyhorse, 2017) was released in July 2017.

Mr. Blaxill earned an M.B.A. with distinction from Harvard Business School and an A.B. from Princeton University's Woodrow Wilson School of Public and International Affairs, where he graduated summa cum laude and Phi Beta Kappa.

DENIAL: How Refusing to Face the Facts about Our Autism Epidemic Hurts Children, Families, and Our Future
By Dan Olmsted and Mark Blaxill